Qu Biologics' Site Specific Immunomodulators (SSIs) are designed to restore normal immune function to treat and prevent cancer and chronic inflammatory diseases.
Helping the Body Heal Itself
Qu Biologics is pioneering the development of SSIs, a first-in-class immunotherapy platform. SSIs emerged from Qu’s seminal discovery that the body’s natural immune response may be harnessed and directed to specific organs. SSIs overcome immune dysfunction that underlies cancer, chronic inflammatory diseases, and aging.
Qu Biologics currently has two Phase 2 randomized double-blind placebo-controlled clinical trials in progress:
Our RESILIENCE Study is designed to evaluate whether Qu’s QBKPN SSI immunomodulator can improve immune function in people 65 years of age or older, including how well it can protect against respiratory and other infections and what effect it has on maintaining or improving quality of life, activity level, and health status.
Our PERIOP-06 Study is designed to evaluate whether Qu’s QBECO SSI can prevent post-operative innate immune suppression and improve survival in people with late-stage colon cancer undergoing surgery for liver metastasis.